Clinical Trial Update: Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial is evaluating saracatinib for idiopathic pulmonary fibrosis and remains active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Saracatinib (saracatinib)

Snippet

Sponsor: National Jewish Health | Conditions: Idiopathic Pulmonary Fibrosis (IPF) | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING